GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » StemRIM Inc (TSE:4599) » Definitions » Capex-to-Operating-Income

StemRIM (TSE:4599) Capex-to-Operating-Income : 0.00 (As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is StemRIM Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

StemRIM's Capital Expenditure for the three months ended in Jan. 2024 was 円0.00 Mil. Its Operating Income for the three months ended in Jan. 2024 was 円-542.19 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


StemRIM Capex-to-Operating-Income Historical Data

The historical data trend for StemRIM's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StemRIM Capex-to-Operating-Income Chart

StemRIM Annual Data
Trend Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Capex-to-Operating-Income
Get a 7-Day Free Trial - 0.37 - - -

StemRIM Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of StemRIM's Capex-to-Operating-Income

For the Biotechnology subindustry, StemRIM's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StemRIM's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemRIM's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where StemRIM's Capex-to-Operating-Income falls into.



StemRIM Capex-to-Operating-Income Calculation

StemRIM's Capex-to-Operating-Income for the fiscal year that ended in Jul. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.35) / 142.392
=0.00

StemRIM's Capex-to-Operating-Income for the quarter that ended in Jan. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -542.191
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


StemRIM  (TSE:4599) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


StemRIM Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of StemRIM's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


StemRIM (TSE:4599) Business Description

Industry
Traded in Other Exchanges
N/A
Address
7-15 Ayato Bio Incubator 3rd floor, Ayato Asagi 7-chome, Prefecture Ibaraki City, Osaka, JPN, 567-0085
StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.

StemRIM (TSE:4599) Headlines

No Headlines